Elan's Tysabri Prompts Morgan Stanley `Overweight' Rating

Aug. 29 (Bloomberg) -- Elan Corporation plc, a specialty pharmaceutical company, was rated ``overweight'' at Morgan Stanley based on their contrarian view of Elan's multiple sclerosis drug, Tysabri. Included are analysts' calls for International Paper Co., Constellation Energy Group Inc., Cabot Corp., Williams-Sonoma Inc., Regency Energy Partners LP, FPIC Insurance Group Inc., Energy Conversion Devices Inc., SY Bancorp Inc. and Domtar Corp.